# Fate Therapeutics, Inc. (FATE)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/FATE/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 3.38M | $ -61.37M | $ -54.58M | $ 75.68M | $ 153.44M |
| 2025 | $ 6.80M | $ -139.57M | $ -114.72M | $ 77.85M | $ 207.18M |
| 2024 | $ 14.33M | $ -195.78M | $ -129.92M | $ 85.27M | $ 318.73M |
| 2023 | $ 68.70M | $ -174.00M | $ -149.66M | $ 103.54M | $ 368.42M |
| 2022 | $ 107.58M | $ -314.71M | $ -317.01M | $ 109.34M | $ 483.94M |
| 2021 | $ 66.38M | $ -252.17M | $ -253.87M | $ 114.82M | $ 678.84M |
| 2020 | $ 40.04M | $ -220.88M | $ -56.26M | $ 97.30M | $ 384.45M |
| 2019 | $ 13.79M | $ -126.69M | $ -116.90M | $ 26.93M | $ 244.76M |
| 2018 | $ 6.26M | $ -87.96M | $ -54.09M | $ 14.88M | $ 160.47M |
| 2017 | $ 5.53M | $ -57.86M | $ -52.04M | $ 14.81M | $ 77.19M |
| 2016 | $ 6.06M | $ -46.04M | $ -41.66M | $ 10.69M | $ 73.15M |
| 2015 | $ 3.41M | $ -42.11M | $ -27.93M | $ 18.24M | $ 38.04M |
| 2014 | $ 0 | $ -36.57M | $ -32.92M | $ 19.63M | $ 28.34M |
| 2013 | $ 0 | $ -29.72M | $ -22.21M | $ 1.73M | $ 50.85M |
| 2012 | $ 1.69M | $ -11.94M | $ -9.83M | $ 3.67M | $ -52.83M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.49 |
| Liabilities / Eq | 0.70 |
| Current Ratio | 4.85 |

## Other views

- [Metrics](https://sponda.capital/en/FATE.md)
- [Charts](https://sponda.capital/en/FATE/charts.md)
- [Compare](https://sponda.capital/en/FATE/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-27.